Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 3/20 | 0.51 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435296 | 0.90 | CENPE (0.41) | CENPETAS1R3TAS1R1 | |
| SCHEMBL13162803 | 0.89 | CENPE (0.50) | CENPEKIFC1MAP4K4MINK1S1PR1 | |
| SCHEMBL2104820 | 0.89 | CENPE (0.50) | CENPEKIFC1MAP4K4MINK1S1PR1 | |
| SCHEMBL2104302 | 0.89 | CENPE (0.55) | CENPEKIFC1MAP4K4MINK1S1PR1 | |
| SCHEMBL2104300 | 0.89 | CENPE (0.55) | CENPEKIFC1MAP4K4MINK1S1PR1 | |
| SCHEMBL3461083 | 0.87 | CENPE (0.49) | CENPEKIFC1MAP4K4MINK1S1PR1 | |
| SCHEMBL2105788 | 0.87 | CENPE (0.49) | CENPEKIFC1MAP4K4MINK1S1PR1 | |
| SCHEMBL3233577 | 0.86 | CENPE (0.52) | CENPEKIFC1MAP4K4MINK1S1PR1 | |
| SCHEMBL4762148 | 0.86 | CENPE (0.52) | CENPEKIFC1MAP4K4MINK1S1PR1 | |
| SCHEMBL3230000 | 0.86 | CENPE (0.54) | CENPEKIFC1MAP4K4MINK1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | claimed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KIFC1 4/4885MAP4K4 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.